Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
3(60%)
Results Posted
100%(2 trials)

Phase Distribution

Ph phase_3
1
20%
Ph not_applicable
1
20%
Ph phase_2
3
60%

Phase Distribution

0

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
3(60.0%)
Phase 3Large-scale testing
1(20.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

5

all time

Status Distribution
Active(3)
Completed(2)

Detailed Status

Active, not recruiting2
Completed2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
3
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 23 (60.0%)
Phase 31 (20.0%)
N/A1 (20.0%)

Trials by Status

recruiting120%
active_not_recruiting240%
completed240%

Recent Activity

3 active trials
Showing 5 of 5
recruitingphase_2

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

NCT06179303
active_not_recruitingphase_2

Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

NCT03941730
active_not_recruitingphase_2

Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease

NCT00080756
completednot_applicable

Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer

NCT01385280
completedphase_3

Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer

NCT00003771

Clinical Trials (5)

Showing 5 of 5 trials
NCT06179303Phase 2

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Recruiting
NCT03941730Phase 2

Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

Active Not Recruiting
NCT00080756Phase 2

Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease

Active Not Recruiting
NCT01385280Not Applicable

Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer

Completed
NCT00003771Phase 3

Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5